Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CD20− / anti-BAFF bispecific antibodies

Anti-CD20− / anti-BAFF bispecific antibodies

US Patent 9951146 · Granted Apr 24, 2018

Estimated economic value: $347,293,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa2024
PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa2024
Anti-CD11D antibodies and uses thereof2024
Anti-human CD19 antibodies2023
CD200R agonist antibodies and uses thereof2022
Pan-ELR+ CXC chemokine antibodies2020
Pan-ELR+ CXC chemokine antibodies2020
Pan-ELR+ CXC chemokine antibodies2018
Pan-ELR+ CXC chemokine antibodies2018
Pan-ELR+ CXC chemokine antibodies2017
Pan-ELR+ CXC chemokine antibodies2017
Anti-BAFF-anti-IL-17 bispecific antibodies2017